Knocking on the door of a million shares volume, a
Post# of 72440
I guess the fact that scientists are interested in OTHER uses for Brilacidin, and THEY want to pay for studying it, finally got some people's attention.
Just think what's going to happen if some morning the email to shareholders includes great news about this, or about the next pill-form clinical trial, or....
name it....